| Date | Time | Source | Headline | Symbol | Company |
| 06/02/2024 | 5:07PM | GlobeNewswire Inc. | Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year | | |
| 06/02/2024 | 5:07PM | GlobeNewswire Inc. | Las enfermedades alérgicas suponen un coste directo de entre 1.800 y 6.600 euros por paciente al año | | |
| 06/02/2024 | 5:07PM | GlobeNewswire Inc. | Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year | | |
| 06/02/2024 | 5:01PM | PR Newswire (Canada) | Avis aux médias - Agenda public du premier ministre du Québec - 3 juin 2024 | | |
| 06/02/2024 | 5:00PM | PR Newswire (Canada) | Media Advisory - Deputy Prime Minister's itinerary for Monday, June 3, 2024 | | |
| 06/02/2024 | 5:00PM | PR Newswire (Canada) | Avis aux médias - Itinéraire de la vice-première ministre pour le lundi 3 juin 2024 | | |
| 06/02/2024 | 4:08PM | GlobeNewswire Inc. | In occasione di ASMS 2024, Biognosys lancia la rivoluzionaria tecnologia P2 Plasma Enrichment per la proteomica del plasma profonda e imparziale | | |
| 06/02/2024 | 4:08PM | GlobeNewswire Inc. | Biognosys lance P2 Plasma Enrichment, une technologie révolutionnaire pour la protéomique approfondie et non biaisée du plasma à la conférence de l’ASMS 2024 | | |
| 06/02/2024 | 4:08PM | GlobeNewswire Inc. | Biognosys stellt auf der ASMS 2024 die bahnbrechende P2 Plasma-Anreicherungstechnologie für unverfälschte, tiefgehende Plasmaproteomik vor | | |
| 06/02/2024 | 4:08PM | GlobeNewswire Inc. | Biognosys lanza en la conferencia anual de la ASMS 2024 la innovadora tecnología de enriquecimiento plasmático P2 para una proteómica plasmática profunda e imparcial | | |
| 06/02/2024 | 4:00PM | PR Newswire (US) | FrogData Unveils Major AI Factory Upgrade to Revolutionize Automotive Retail Operations | | |
| 06/02/2024 | 3:45PM | PR Newswire (US) | izmostock Unveils Revolutionary Image Solution for Leasing Industry, Driving Unparalleled ROI and User Engagement | | |
| 06/02/2024 | 3:00PM | PR Newswire (Canada) | Conférence de presse du ministre de la Justice et du ministre de la Sécurité publique | | |
| 06/02/2024 | 2:53PM | PR Newswire (US) | GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology | | |
| 06/02/2024 | 2:32PM | Business Wire | TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
| 06/02/2024 | 2:23PM | PR Newswire (Canada) | AVIS - Voie de contournement ferroviaire à Lac-Mégantic: point de presse de Christine Labrie et de groupes de la société civile | | |
| 06/02/2024 | 1:00PM | PR Newswire (Canada) | /R E P E A T -- Media Advisory - Minister Wilkinson announces funding and measures to protect Southern Resident killer whales/ | | |
| 06/02/2024 | 1:00PM | PR Newswire (Canada) | /R E P R I S E -- Avis aux médias - Le ministre Wilkinson annonce des investissements et des mesures pour protéger les épaulards résidents du Sud/ | | |
| 06/02/2024 | 12:40PM | PR Newswire (US) | GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology | | |
| 06/02/2024 | 12:40PM | PR Newswire (Canada) | GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology | | |
| 06/02/2024 | 12:30PM | GlobeNewswire Inc. | Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting | NASDAQ:MRUS | Merus NV |
| 06/02/2024 | 12:30PM | GlobeNewswire Inc. | Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting | TG:2GH | Merus NV |
| 06/02/2024 | 12:30PM | GlobeNewswire Inc. | Merus : présentation des données provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab lors du congrès annuel 2024 de l’ASCO® | TG:2GH | Merus NV |
| 06/02/2024 | 12:30PM | Business Wire | CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination | | |
| 06/02/2024 | 12:30PM | GlobeNewswire Inc. | Merus präsentiert Zwischenergebnisse zu MCLA-145 als Monotherapie und in Kombination mit Pembrolizumab auf der ASCO®-Jahrestagung 2024 | TG:2GH | Merus NV |
| 06/02/2024 | 12:30PM | PR Newswire (US) | Miami Beach Inspires this Summer with Film, Fashion and Music Experiences | | |
| 06/02/2024 | 12:25PM | PR Newswire (Canada) | Avis aux médias - Agents de la paix en services correctionnels - Le TSO : pas juste dans la santé qu'il y en a | | |
| 06/02/2024 | 12:09PM | Business Wire | Stronger Than Ever: Adani Portfolio Delivers Record Performance | | |
| 06/02/2024 | 11:32AM | PR Newswire (US) | Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479 | | |
| 06/02/2024 | 11:31AM | GlobeNewswire Inc. | KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering | | |